How effective is Mobocertinib from Bangladesh Zisika Pharmaceuticals?

Mobocertinib (Mobocertinib) produced by Bangladesh Ziskar Pharmaceuticals belongs to the production category of generic drugs. Its drug ingredients are basically the same as those of the original drug Mobocertinib. There may be only a difference in price. Specifications The price of each box of 40mg*60 tablets is around 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap. Mobotinib is also known as TAK-788 and has the trade name exkivity.

Mobotinib is suitable for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The recommended dose is 160 mg orally once daily. Mobotinib is a small molecule tyrosine kinase inhibitor whose molecular target is the mutated exon 20 region of the epidermal growth factor receptor (EGFR) gene. Mobotinib is also an irreversible kinase inhibitor that forms a covalent bond with cysteine u200bu200b797 in the active site of EGFR, resulting in sustained inhibition of EGFR enzyme activity. Irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild-type (WT) EGFR. After oral administration of mobotinib, two pharmacologically active metabolites (AP32960 and AP32914) with inhibitory properties similar to those of mobotinib can be found in the plasma.

It is understood that Mobotinib is currently on the market in China under the name Mobosetinib. Due to its short time on the market, it has not yet been included in the medical insurance. The original drug Mobotinib, produced by Japan's Takeda Pharmaceuticals and sold in Hong Kong, China, has specifications of 40mg*30 tablets and the price is around RMB 7,000 (the price may fluctuate due to the exchange rate). It is relatively expensive. For specific prices and drug details, please consult Yade's medical consultant.